Tezepelumab

Drug Profile

Tezepelumab

Alternative Names: AMG 157; Anti-TSLP MAb; MEDI-9929

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bispebjerg Hospital; Lund University; MedImmune; University of Copenhagen; University of Newcastle, Australia
  • Class Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Thymic stromal lymphopoietin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Atopic dermatitis

Most Recent Events

  • 01 Mar 2017 Medimmune completes a phase II trial in Asthma in USA, Bulgaria, Czech Republic, Hungary, Israel, Japan, Latvia, Lithuania, Serbia, South Africa, Ukraine and Slovakia (NCT02054130; EudraCT2013-003269-33)
  • 15 Dec 2016 Biomarkers information updated
  • 01 Aug 2016 Phase-II clinical trials in Asthma (Treatment-experienced) in Denmark (IV) (NCT02698501)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top